CASICASI Pharmaceuticals Inc (NASDAQ:CASI) Historically, October is always a great month for a trend reversal on this name. I think we could see a strong reversal over the coming wks.Longby SmoothJBPublished 1
CASICASI Pharmaceuticals, Inc. (CASI) is still in bottoming mode. The technical indicators are looking better now for the stock. The MACD is starting to rise, confirming a bullish divergence has taken form and the Stochastic also has a bullish crossover. It might attempt to breakout above the $1.25 level on Monday and if it succeeds we should expect a strong move to the upside. It has the potential to make another big run next week, so keep a close eye on CASI and don’t miss the trade. The price target of the two Wall Street analysts that rated the stock since the last quarterly report is $3.9Longby SmoothJBPublished 0
CASICASI Pharmaceuticals Inc (NASDAQ:CASI) The daily chart is shaping up and I expect the next point of resistance to be at $2.25. At some point CASI will take off and never look back. I think that day will come soon and those buying at these prices will be thanking me down the road. Oppenheimer analyst Leland Gershell recently raised the price target on CASI to $6.00 (from $5.00) while maintaining Outperform rating and the CEO purchased 480000 shares in August owning more than 5 million shares. I think CASI is heading higher from here and will make an excellent trade going forward.Longby SmoothJBPublished 1
$CASI is gonna fall todayPupm&Dump trading strategy idea. $CASI is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $1,67; stop-loss — $1,84; take-profit — $1,32/MOC Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!Shortby KozakHlibPublished 1
CASIThursday's earnings report news has lit a fire under CASI Pharmaceuticals (NASDAQ: CASI) and I don't think it will be put out anytime soon. This looks like the start of a prolonged rally, one that could see this stock trading +400% higher than current levels according to Oppenheimer analyst Leland Gershell that yesterday raised the price target on CASI to $6.00 (from $5.00) while maintaining Outperform rating. From a technical perspective, the stock broke the long-term downtrend line yesterday with some volume if it can stay above this downtrend resistance level, next possible upside resistance may be around the 1.80 level. CASI remains, in my view, undervalued, and based upon recent actions by the company, I think the stock price should head higher. The way to make money in these markets is to find the undervalued stock before the market does. Let's keep an eye on her.Longby SmoothJBPublished 2
CASI - Long SetupStrong buying from COB/CEO in March at $2.06 and strong buying last year as well from same insider. Break 1.78, Stop signal 1.47. First target 2.33, Second target Momentum. Longby AcornWealthCorpPublished 3
CASICASI Pharmaceuticals Inc (NASDAQ:CASI) moved up about 9.22% on strong volume last week and it looks like a lot of traders booked gains from the upwards run, but I did exactly the opposite. With the resistance level already identified on the charts and with the huge insider activity revealed, I used the pullback to take a big long position. Usually when insiders buy shares, especially in large amounts it is a sign that positive things are coming. If CASI can keep going up and break the resistance at 2.50 this could further confirm the uptrend and would give a measured move target of nearly 3.25Longby SmoothJBPublished 111
$CASI KST Buy Signal CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited; Juventas Cell Therapy Ltd.; Pharmathen Global BV; and Cleave Therapeutics, Inc. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.Longby UnknownUnicorn19246015Published 1
$CASI CASI Pharma Moving on CEO Purchase Interesting insider buying with a 3mil share purchase by the CEO Will be on watch tomorrow for trend-line breakout He Wei-Wu Chairman and CEO Mar 26 Buy 2.05 3,000,000 6,150,000 3,000,000 Longby Xclusive-TradingPublished 12
CASI PHARMACEUTICALS daily analysisHi friends the daily analysis shows that it will experience with a high probability an uptrend but at the same time you have to be vigilant of the change towards the opposite directionLongby YL_PROPublished 222
CASI Pharmaceuticals, Inc. Bullish Targets CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.Longby DEXWireNewsPublished 111
$CASI : SmlCap play with 1-3 RR for 30-40% profitplease see boxes on chart for Entry, Exit and Stop Loss zonesLongby ram10kkUpdated 220
CASI PHARMACEUTICAL INCthe price can rebound on resistance or continue to rise by forming a breakout, watch the price on resistanceby ludopro45Published 0
High Traffic Pivots on CASI ChartCASI saw a nice bump in after-hours trading Friday. Shares hit $1.88. Can the Oppenheimer analyst rating be enough of a catalyst to carry through this momentum into the week ahead is the biggest question. Great volume on Friday but is it all for nothing? "What had sparked some excitement came in light of new analyst activity. Oppenheimer analyst Leland Gershell initiated coverage on CASI. The analyst gave it an Outperform rating and announced a price target of $5. That represents a 182% premium to Friday’s closing price for CASI stock." Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Eventsby PennyStocks101Published 1
Invest IDEA CASI openinsider. com/search?q=CASI insider BUY CASI Zhang Larry Pres P - Purchase $1.90 +20,153 20,153 New +$38,291 CASI He Wei-Wu COB, CEO, 10% P - Purchase $1.90 +4,152,426 12,809,942 +48% +$7,889,609 Longby AlexandrKrupenychPublished 0
CASI CASI = CEO He Wei-wu Bought 4,152,426 shares × $1.90 = $7,889,609 Share count: 12,809,942 shares .. If you want to understand where the money is invested and have returns on it, follow what the owners or internal managers perform ... The curriculum of each of them always leaves traces and makes it clear what they are capable of. Wei-Wu He: this guy made a fortune building and selling biotech companies. Him buying millions of shares looks like he knows what he’s doingLongby mauretto432Published 7
CASI Pharmaceuticals, Inc. $3.20 target CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.Longby DEXWireNewsPublished 16
Casi Pharma CEO Buys $1.5 million in stock CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong and Macau. Its products include ZEVALIN, EVOMELA and MARQIBO. CASI Pharmaceuticals was founded in 1991 and is headquartered in Rockville, MD.by DEXWireNewsPublished 1113
CASI Pharmaceuticals Inc (CASI) Yahoo finance “CASI Pharmaceuticals Inc (CASI), a biopharmaceutical company dedicated to developing high-quality products and therapeutics to the global health market, announced earlier this month that it had received National Medical Products Administration approval of Melphalan Hydrochloride For Injection. CASI Pharmaceuticals Executive Chairman Wei-Wu He, Ph.D., commented, ''NMPA approval of Melphalan Hydrochloride For Injection (EVOMELA®) is encouraging news for patients in China with multiple myeloma as there is no commercially available melphalan formulation in the country. EVOMELA's approval, therefore, addresses a significant unmet medical need. In addition, EVOMELA®‘s proprietary formulation of melphalan, a first-line therapy for multiple myeloma patients, offers considerable clinical advantages as it does not contain propylene glycol, which may cause side effects, it has long stability when reconstituted for infusion, and is the only intravenous melphalan product approved for use in the high-dose conditioning indication in pre-transplant therapy.'' This is one I feel has great growth potential. Good thing as well at there is more institutional investors than general public shows investors have a lot of confidence in the company. Again, I’m not giving financial advice and you should check things out for yourself. Just sharing my thoughts Longby SkinwahPublished 6